Hepatitis B virus screening before chemotherapy for lymphoma: A cost-effectiveness analysis

Journal of Clinical Oncology

Volumn 30, Issue 26, 2012, Pages 3167-3173

  Zurawska, Urszula ^a   Hicks, Lisa K ^a,b,d   Woo, Gloria ^a,e   Bell, Chaim M ^a,b,d   Krahn, Murray ^e   Chan, Kelvin K ^a,c   Feld, Jordan J ^a,f  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; HEPATITIS B SURFACE ANTIGEN; PREDNISONE; RITUXIMAB; VINCRISTINE;

AGED; ANTIVIRAL THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEALTH INSURANCE; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HUMAN; INFECTION RISK; LOW RISK POPULATION; LYMPHOMA; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; VIRUS EXAMINATION; VIRUS REACTIVATION;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; DECISION SUPPORT TECHNIQUES; DOXORUBICIN; EARLY DIAGNOSIS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; PREDNISONE; TREATMENT OUTCOME; VINCRISTINE; VIRUS ACTIVATION;

EID: 84866525059     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.7510     Document Type: Article

References (50)

1. Weinbaum CM, Williams I, Mast EE, et al: Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 57:1-20, 2008
2. McQuillan GM, Coleman PJ, Kruszon-Moran D, et al: Prevalence of hepatitis B virus infection in the United States: The National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 89:14-18, 1999 (Pubitemid 29281961)
3. Lubel JS, Testro AG, Angus PW: Hepatitis B virus reactivation following immunosuppressive therapy: Guidelines for prevention and management. Intern Med J 37:705-712, 2007 (Pubitemid 47481164)
4. Hoofnagle JH, Dusheiko GM, Schafer DF, et al: Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann InternMed96:447-449, 1982 (Pubitemid 12139868)
5. Lok AS, McMahon BJ: Chronic hepatitis B: Update of recommendations. Hepatology 39:857-861, 2004 (Pubitemid 38337668)
6. Lau GK, Yiu HH, Fong DY, et al: Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125:1742-1749, 2003 (Pubitemid 37500439)
7. Loomba R, Rowley A, Wesley R, et al: Systematic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148:519-528, 2008 (Pubitemid 351665421)
8. Yeo W, Chan TC, Leung NW, et al: Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27:605-611, 2009
9. Hsu C, Hsiung CA, Su IJ, et al: A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial. Hepatology 47:844-853, 2008 (Pubitemid 351449676)
10. Khokhar OS, Farhadi A, McGrail L, et al: Oncologists and hepatitis B: A survey to determine current level of awareness and practice of antiviral prophylaxis to prevent reactivation. Chemotherapy 55:69-75, 2009
11. Lee R, Vu K, Bell CM, et al: Screening for hepatitis B surface antigen before chemotherapy: Current practice and opportunities for improvement. Curr Oncol 17:32-38, 2010
12. Artz AS, Somerfield MR, Feld JJ, et al: American Society of Clinical Oncology provisional clinical opinion: Chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 28:3199-3202, 2010
13. Barry M, Mulcahy F, Merry C, et al: Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 36:289-304, 1999 (Pubitemid 29201737)
14. Lai CL, Chien RN, Leung NW, et al: A one-year trial of lamivudine for chronic hepatitis B: Asia Hepatitis Lamivudine Study Group. N Engl J Med 339:61-68, 1998 (Pubitemid 28304879)
15. Lai CL, Shouval D, Lok AS, et al: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354:1011-1020, 2006 (Pubitemid 43357805)
16. Saab S, Dong MH, Joseph TA, et al: Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: A decision analysis model. Hepatology 46:1049-1056, 2007 (Pubitemid 350144770)
17. Day FL, Karnon J, Rischin D: Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. J Clin Oncol 29:3270-3277, 2011
18. Bank of Canada: Inflation calculator. 2011. http://www.bankofcanada.ca/ rates/related/inflation-calculator/
19. Lok AS, McMahon BJ: Chronic hepatitis B: Update 2009. Hepatology 50:661-662, 2009
20. 2006 Census: Place of birth for the immigrant population by period of immigration, 2006 counts and percentage distribution, for Canada, provinces and territories -20% sample data. http://www12.statcan.ca/census-recensement/2006/ dp-pd/hlt/97-557/T404-eng.cfm?Lang=E&T=404&GH=4&GF=1&SC=1&S= 1&O=D
21. Leber A, Sherman M: Estimation of immigration related chronic hepatitis B infection and hepatocellular carcinoma development in Canada from 1981-2006. Presented at the 5th Annual Winter Meeting of the Canadian Association for the Study of the Liver, Banff, Alberta, Canada, February 27-March 2, 2009
22. Dai MS, Chao TY, Kao WY, et al: Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 83:769-774, 2004
23. He YF, Li YH, Wang FH, et al: The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma. Ann Hematol 87:481-485, 2008
24. Kim JS, Hahn JS, Park SY, et al: Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma. Yonsei Med J 48:78-89, 2007 (Pubitemid 46403637)
25. Idilman R, Arat M, Soydan E, et al: Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat 11:141-147, 2004 (Pubitemid 38365765)
26. Lee GW, Ryu MH, Lee JL, et al: The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy. J Korean Med Sci 18:849-854, 2003
27. Li YH, He YF, Jiang WQ, et al: Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 106:1320-1325, 2006
28. Pei SN, Chen CH, Lee CM, et al: Reactivation of hepatitis B virus following rituximab-based regimens: A serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 89:255-262, 2010
29. Rossi G, Pelizzari A, Motta M, et al: Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 115:58-62, 2001 (Pubitemid 32995093)
30. Shibolet O, Ilan Y, Gillis S, et al: Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 100:391-396, 2002 (Pubitemid 34761098)
31. Faggioli P, De Paschale M, Tocci A, et al: Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin's lymphoma. Haematologica 82:38-42, 1997 (Pubitemid 28023485)
32. Picardi M, Pane F, Quintarelli C, et al: Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: High prevalence of acquired viral genomic mutations. Haematologica 88:1296-1303, 2003 (Pubitemid 37456385)
33. Yeo W, Chan PK, Zhong S, et al: Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol 62:299-307, 2000
34. Sehn LH, Berry B, Chhanabhai M, et al: The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857-1861, 2007 (Pubitemid 46348180)
35. Feugier P, Van Hoof A, Sebban C, et al: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126, 2005 (Pubitemid 46211317)
36. Kwak LW, Halpern J, Olshen RA, et al: Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. J Clin Oncol 8:963-977, 1990 (Pubitemid 20200184)
37. Sherman M, Shafran S, Burak K, et al: Management of chronic hepatitis B: Consensus guidelines. Can J Gastroenterol 21:5C-24C, 2007 (suppl C) (Pubitemid 47162250)
38. Ontario Ministry of Health and Long-Term Care: Ontario health insurance (OHIP) schedule of benefits and fees: Schedule of benefits for laboratory services. http://www.health.gov.on.ca/english/providers/program/ohip/sob/lab/ lab-services-sched-01-19990401.pdf
39. Ontario Ministry of Health and Long-Term Care: Schedule of benefits for physician services under the Health Insurance Act. Effective June 5, 2012. http://www.health.gov.on.ca/english/providers/program/ohip/sob/physserv/ a-consul.pdf
40. Ontario Ministry of Health and Long-Term Care: Ontario public drug programs: Formulary - Drugs funded by Ontario Drug Benefit Program. https://www.healthinfo.moh.gov.on.ca/formulary/index.jsp
41. Fassbender K, Fainsinger RL, Carson M, et al: Cost trajectories at the end of life: The Canadian experience. J Pain Symptom Manage 38:75-80, 2009
42. Wong WW, Woo G, Jenny Heathcote E, et al: Cost effectiveness of screening immigrants for hepatitis B. Liver Int 31:1179-1190, 2011
43. Tabár L, Vitak B, Chen TH, et al: Swedish two-county trial: Impact of mammographic screening on breast cancer mortality during 3 decades. Radiology 260:658-663, 2011
44. Telford JJ, Levy AR, Sambrook JC, et al: The cost-effectiveness of screening for colorectal cancer. CMAJ 182:1307-1313, 2010
45. Schröder FH, Hugosson J, Roobol MJ, et al: Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366:981-990, 2012
46. Liberato NL, Marchetti M, Barosi G: Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 25:625-633, 2007 (Pubitemid 350002916)
47. Aballéa S, Chancellor JV, Raikou M, et al: Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/ leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer 109:1082-1089, 2007 (Pubitemid 46435386)
48. Best JH, Hornberger J, Proctor SJ, et al: Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma. Value Health 8:462-470, 2005 (Pubitemid 41726099)
49. Tappenden P, Jones R, Paisley S, et al: The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. Eur J Cancer 43:2487-2494, 2007 (Pubitemid 350086932)
50. Bradbury PA, Tu D, Seymour L, et al: Economic analysis: Randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J Natl Cancer Inst 102:298-306, 2010